USFDA gives tentative approval to Zydus’s Levomilnacipran extended-release capsules
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
The United States Food and Drugs Administration (USFDA) has given tentative approval to Zydus Lifesciences to market Levomilnacipran extended-release capsules, 20 mg, 40 mg, 80 mg and 120 mg, according to a company statement.
Levomilnacipran is a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, the statement said.